Population Bioequivalence (PBE) analysis for in-vitro studies [Regulatives / Guidelines]

posted by balakotu – India, 2019-05-22 07:41  – Posting: # 20288
Views: 720

(edited by balakotu on 2019-05-23 07:07)

Dear All,

any one help to below topic..............

Population Bioequivalence (PBE) analysis is required for in-vitro studies as per FDA guidance for few products like Iron Sucrose Injection, Ciclosporine Ophthalmic Emulsion, Azelastine Nasal spray etc.

For performing PBE analysis there are two statistical methods
1. One-sided PBE
2. Traditional PBE

Which method is most preferable out of the two methods?

If the study is meeting criteria as per one-sided PBE analysis & not meeting the criteria as per the traditional PBE analysis, whether that study will be accepted by regulatory?

Which is the better method for PBE analysis that regulatory will accept?

Thanks& Regards
Kotu.

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,818 posts in 4,201 threads, 1,361 registered users;
online 5 (0 registered, 5 guests [including 4 identified bots]).
Forum time (Europe/Vienna): 05:44 CEST

If I find 10,000 ways something won’t work, I haven’t failed.
I am not discouraged, because every wrong attempt discarded
is another step forward.    Thomas Alva Edison

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5